Regulatory Inspection Outcome
Ajanta Pharma receives US FDA Form 483 with 5 observations for Paithan facility
NSE
ajantpharm
BSE
532331
Ajanta Pharma announced that the US FDA inspection at its Paithan facility concluded with the issuance of Form 483 containing 5 observations, indicating regulatory concerns that require corrective action.
PRICE-SENSITIVE TRIGGER
Event: US FDA inspection outcome (Form 483 issued)
Type: Regulatory Inspection Outcome
Impact: Negative
Immediate Effect: Raises regulatory risk and potential compliance concerns, which may impact future approvals and exports if not resolved
Financial Snapshot
- Number of observations: 5
- Inspection period: April 13–21, 2026
Highlight:
- US FDA issued Form 483 with 5 observations post inspection
What Happened ?
The US FDA conducted an inspection at Ajanta Pharma’s manufacturing facility in Paithan, Maharashtra, from April 13 to April 21, 2026. The inspection concluded with the issuance of a Form 483 containing 5 observations.
key highlights
Inspection Outcome
- US FDA inspection completed at Paithan facility
- Issuance of Form 483 with 5 observations
- Indicates procedural or compliance gaps identified
Regulatory Context
- Form 483 is issued when investigators observe potential violations of FDA regulations
- Observations may range from minor procedural issues to more serious compliance concerns
Company Action
- Company has stated it will respond within the stipulated timeline
Note:
- Severity of observations is not disclosed, which is critical for assessing real impact
Risk Analysis
Key Risks
- Escalation to Warning Letter if response is inadequate
- Delay in product approvals or filings
- Impact on exports to US market
- Reputational risk in regulated markets
Worst Case Scenario
- Failure to satisfactorily address observations could lead to a Warning Letter or import restrictions, impacting revenue from US operations.
Risk Level: Medium
Company Commentary
- Inspection conducted between April 13–21, 2026
- Facility: Paithan, Maharashtra
- Received Form 483 with 5 observations
- Company will respond within stipulated timeline
Official Exchange Filing: Ajanta Pharma Limited